Lexaria Bioscience (LEXX) Registration filing summary

Company overview and business model

• Focuses on enhancing bioavailability of active pharmaceutical ingredients using patented DehydraTECH™ technology, which improves absorption and effectiveness of APIs in various formats, including pharmaceuticals, nutraceuticals, and consumer goods.

• DehydraTECH can be applied to a wide range of molecules, such as GLP-1, GIP, vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, nicotine, and cannabinoids, targeting indications like diabetes, weight loss, hypertension, and heart disease.

• Business model includes licensing DehydraTECH to industry participants for integration into their products, supporting both developmental and commercial stage offerings.

Financial performance and metrics

• Aggregate market value of outstanding common stock held by non-affiliates is approximately $32.5 million, based on 17,552,594 shares at $1.94 per share as of January 21, 2025.

• $3.6 million of securities sold in the 12 months ending with the date of the prospectus.

Use of proceeds and capital allocation

• Net proceeds intended for working capital and general corporate purposes, including research and development, patent and legal costs, potential share repurchases, and reduction of indebtedness.

• Pending specific application, funds may be invested in short-term marketable securities.